|
|
 |
April 8, 2008 |
Now Available:
Download the podcast of Dr. Heffernan's presentation
With biweekly and special edition newsletters, Musculoskeletal Report is the top online resource for staying abreast of the most current and clinically relevant information in the field of musculoskeletal disease and treatment.
MSK Report provides cutting-edge scientific updates through in-depth interviews, on-location coverage of medical meetings, expert-led panel discussions, and live newscasts. With an editorial board of internationally recognized thought leaders, MSK Report is positioned to provide unparalleled quality news reporting with the highest level of credibility.
MSK Video Report:
Dr. Michael P. Heffernan presents "Biologics for Psoriasis: Individualizing Therapy - Who is the Right Patient" from our 5-part series, "Practical Approaches to Solving Psoriasis Challenges"
Arthritis: Analysis Finds Etanercept, Adalimumab More Cost-Effective Than Infliximab for Medicare Use
A model comparing costs and effectiveness of the biologics currently covered for treating RA in US Medicare beneficiaries has shown that etanercept (ETN) and adalimumab (ADA) are both more cost-effective than infliximab (INF)...
Skin: Seven New Psoriasis Risk Genes Identified
A genome-wide study has identified 7 new genes that appear to increase a person's risk for psoriasis...
Arthritis: Work Disability Still High in RA, But May Be Improving
More than one third of RA patients become unable to work for at least some period within 10 years' disease duration. Of those, 39% eventually return to work, >40% blame their RA for their work disability, and work disability appears to have decreased substantially in patients with long-standing RA over the past 15 to 20 years...
Consumer News: Testosterone Therapy May Reduce Bone Loss in Older Men
Testosterone injections may improve bone density and prevent osteoporosis in older men with low testosterone levels...
New from PubMed: Does Physical Therapy Still Have a Place in the Treatment of Ankylosing Spondylitis?
Researchers believe that pharmacological advancements in the treatment of ankylosing spondylitis do not replace traditional physical therapy programs...
BioPharm Business: Radius Fills Enrollment of Phase II Trial of BA058 for Osteoporosis in Postmenopausal Women; Milestone Triggers $28.3 Million Financing
Radius Health, Inc announced the completion of patient enrollment in its phase II clinical trial of BA058, an analog of hPTHrP (human parathyroid hormone-related protein)...